Tuesday, June 06, 2017 6:21:23 AM
Thanks for your opinion, I tend to agree. I'm not a penny flipper in this name, for sure. I have traded this one pretty often in the good old days, not that intensive like Harry and his crew did, but for nice gains too.
Appreciate your feedback
Appreciate your feedback
Recent CLDX News
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/29/2026 09:36:10 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2026 12:00:16 PM
- Celldex to Present at Upcoming Investor Conference • GlobeNewswire Inc. • 04/13/2026 08:01:00 PM
- Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares • GlobeNewswire Inc. • 04/06/2026 02:53:52 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/02/2026 09:14:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:08:18 PM
- Celldex Announces Pricing of $300 Million Public Offering of Common Stock • GlobeNewswire Inc. • 04/02/2026 01:48:19 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/01/2026 08:07:34 PM
- Celldex Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 04/01/2026 08:01:00 PM
- Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026 • GlobeNewswire Inc. • 03/27/2026 02:30:00 PM
- Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease • GlobeNewswire Inc. • 03/01/2026 02:45:00 PM
- Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI • GlobeNewswire Inc. • 02/27/2026 07:45:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/25/2026 09:06:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 09:01:27 PM
- Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/25/2026 09:01:00 PM
- Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria • GlobeNewswire Inc. • 02/25/2026 12:01:00 PM
- Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile • GlobeNewswire Inc. • 02/23/2026 01:01:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/10/2026 04:21:52 PM
- Celldex to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/09/2026 01:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/17/2025 09:06:34 PM
- Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism • GlobeNewswire Inc. • 12/09/2025 01:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2025 09:20:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/04/2025 09:04:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2025 09:17:07 PM
